Physician profile
Matthew D Doyle
NPI 1538412044
$8,993.44
in general payments reported to CMS, 2019-2025
25 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $311 · 2021: $1,123 · 2022: $752 · 2023: $1,969 · 2024: $2,173 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,849.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,734.78 | 2019-2025 | Cequa |
| Alcon Vision LLC | $1,461.55 | 2019-2025 | Rocklatan, Tryptyr, Total30 |
| Novartis Pharmaceuticals Corporation | $954.82 | 2019-2023 | |
| Abbvie INC. | $683.40 | 2022-2025 | Lumigan, Vuity, Alphagan P |
| Oyster Point Pharma, INC. | $612.49 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $549.20 | 2019-2021 | |
| Biotissue Holdings INC. | $449.71 | 2022-2024 | |
| Coopervision INC. | $424.41 | 2019-2024 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $331.51 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $274.93 | 2023-2025 | Miebo, Xiidra, Infuse |
| Allergan, INC. | $241.44 | 2019-2022 | |
| Dompe US, INC. | $238.06 | 2019-2025 | Oxervate |
| Sight Sciences, INC. | $183.81 | 2019-2021 | |
| Horizon Therapeutics Plc | $174.80 | 2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $133.40 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $112.33 | 2024 | Tepezza |
| Visioneering Technologies, INC. | $85.30 | 2019 | |
| Astellas Pharma US INC | $71.21 | 2024 | Izervay |
| Abb Con-Cise Optical Group LLC | $65.32 | 2022-2025 | Contact Lens, Spectacle Lenses |
| Kala Pharmaceuticals, INC. | $52.91 | 2021 | |
| Thea Pharma INC. | $46.12 | 2023-2024 | Iyuzeh |
| Optos, INC. | $38.92 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $35.69 | 2021-2023 | Acuvue |
| Lombart Brothers, INC. | $22.90 | 2024 | Opd-III |
| Spark Therapeutics, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.